Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE:ABBV) and Gedeon Richter Plc have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. 

  • The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. 
  • AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (Vraylar/Reagila).
  • Under the terms of the agreement, the collaboration includes both preclinical and clinical R&D activities with shared financing by the parties. 
  • Richter will receive an upfront cash payment, along with a potential milestone payment, as well as sales-based royalties. 
  • Specific deal terms were not disclosed.
  • AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries, and Vietnam.
  • The transaction is expected to close in Q2 of 2022.
  • Price Action: ABBV shares are up 0.89% higher at $150.50 during the premarket session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.